2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid
Title | Journal |
---|---|
An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. | Nature medicine 20130301 |
Neuron-specific non-classical release of prothymosin alpha: a novel neuroprotective damage-associated molecular patterns. | Journal of neurochemistry 20121001 |
Amlexanox is as effective as dexamethasone in topical treatment of erosive oral lichen planus: a short-term pilot study. | Oral surgery, oral medicine, oral pathology and oral radiology 20120501 |
Development of a measure to assess effective listening and interactive communication skills in the delivery of children's rehabilitation services. | Disability and rehabilitation 20120101 |
New Evidence-Based Treatment Approach in Behçet's Disease. | Pathology research international 20120101 |
Clinical inquiry. What is the most effective way to treat recurrent canker sores? | The Journal of family practice 20111001 |
Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents. | Expert opinion on emerging drugs 20110301 |
Nicolaus Copernicus: not only a great astronomer but also a physician. | Journal of nephrology 20110101 |
Variable initial swing side and prolonged double limb support represent abnormalities of the first three steps of gait initiation in patients with Parkinson's disease with freezing of gait. | Frontiers in neurology 20110101 |
Molecular level interactions of S100A13 with amlexanox: inhibitor for formation of the multiprotein complex in the nonclassical pathway of acidic fibroblast growth factor. | Biochemistry 20100323 |
Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1. | Biochemical pharmacology 20090615 |
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. | Journal of translational medicine 20090101 |
A clinical evaluation of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial. | Trials 20090101 |
PDE4 inhibitors: current status. | British journal of pharmacology 20081001 |
[Local Treatment of stomatitis aphthosa]. | Medizinische Monatsschrift fur Pharmazeuten 20080901 |
Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. | Clinical ophthalmology (Auckland, N.Z.) 20080901 |
Synergistic Ca2+ and Cu2+ requirements of the FGF1-S100A13 interaction measured by quartz crystal microbalance: an initial step in amlexanox-reversible non-classical release of FGF1. | Neurochemistry international 20080501 |
Review of over-the-counter treatments for aphthous ulceration and results from use of a dissolving oral patch containing glycyrrhiza complex herbal extract. | The journal of contemporary dental practice 20080301 |
Effectiveness of two oral pastes for the treatment of recurrent aphthous stomatitis. | Oral diseases 20070901 |
Mucocutaneous lesions of Behcet's disease. | Yonsei medical journal 20070831 |
An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20061001 |
Evidence for serum-deprivation-induced co-release of FGF-1 and S100A13 from astrocytes. | Neurochemistry international 20060801 |
A late cutaneous response in actively sensitized rats: a new method for evaluating the efficacy of antiallergic drugs. | Journal of pharmacological sciences 20060801 |
Voltage-dependent N-type Ca2+ channel activity regulates the interaction between FGF-1 and S100A13 for stress-induced non-vesicular release. | Cellular and molecular neurobiology 20060501 |
The efficacy of amlexanox OraDisc on the prevention of recurrent minor aphthous ulceration. | Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20060201 |
Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. | Mediators of inflammation 20060101 |
Molecular mechanism of inhibition of nonclassical FGF-1 export. | Biochemistry 20051129 |
A comparative study of the efficacy of Aphtheal in the management of recurrent minor aphthous ulceration. | Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20050801 |
Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
Amlexanox for the treatment of recurrent aphthous ulcers. | Clinical drug investigation 20050101 |
Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. | The Biochemical journal 20030901 |
Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. | Biochemical and biophysical research communications 20020412 |
Selecting topical and systemic agents for recurrent aphthous stomatitis. | Cutis 20010901 |
The precursor but not the mature form of IL1alpha blocks the release of FGF1 in response to heat shock. | The Journal of biological chemistry 20010216 |
Treatment strategies for recurrent oral aphthous ulcers. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010101 |
The comparative release of FGF1 by hypoxia and temperature stress. | Growth factors (Chur, Switzerland) 20010101 |
Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase. | International archives of allergy and applied immunology 19870101 |